TY  - JOUR
AU  - Garcia, J L
AU  - Lozano, R
AU  - Misiewicz-Krzeminska, I
AU  - Fernandez-Mateos, J
AU  - Krzeminski, P
AU  - Alfonso, S
AU  - Marcos, R A
AU  - Garcia, R
AU  - Gomez-Veiga, F
AU  - Virseda, A
AU  - Herrero, M
AU  - Olmos, D
AU  - Cruz-Hernandez, J J
PY  - 2017
DO  - 10.1007/s12094-017-1675-5
UR  - http://hdl.handle.net/10668/11290
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the...
LA  - en
PB  - Springer
KW  - AR-V7
KW  - Androgen receptor
KW  - CD133
KW  - Capillary nano-immunoassay
KW  - Circulating tumor cells
KW  - PTEN
KW  - AC133 Antigen
KW  - Alternative Splicing
KW  - Biomarkers, Tumor
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunoassay
KW  - Male
KW  - Nanomedicine
KW  - Neoplastic Cells, Circulating
KW  - Pilot Projects
KW  - Prognosis
KW  - Prostatic Neoplasms
KW  - Receptors, Androgen
TI  - A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
TY  - research article
VL  - 19
ER  -